Infleqtion, in collaboration with the University of Chicago (UChicago) and the Massachusetts Institute of Technology (MIT), has been selected to advance to Phase 3 of the Wellcome Leap Quantum for Bio (Q4Bio) Challenge. This final stage involves a 12-month validation period supported by $2 million in research funding to transition quantum-enabled biomarker discovery from theoretical simulations to experimental execution on real quantum hardware. The project focuses on the computational challenge of feature selection in high-dimensional oncology datasets, specifically aiming to forecast treatment responses for head-and-neck cancer using a curated clinical cohort from UChicago.
The technical core of the project is a hybrid quantum-classical workflow utilizing Hyper-RQAOA (HRQAOA), a specialized quantum routine designed for the limitations of near-term hardware. HRQAOA optimizes the Recursive Quantum Approximate Optimization Algorithm (RQAOA) by implementing parameter transfer techniques, where parameters learned on classically simulable subproblems are used to initialize larger, more complex quantum circuits. This approach captures higher-order interactions across multimodal data—including DNA, RNA, and pathology image features—that are often bypassed by traditional classical approximations. The objective is to demonstrate Empirical Quantum Advantage (EQA) by producing clinically useful biomarker sets (typically under 35 features) with higher predictive accuracy than state-of-the-art classical methods.
This selection coincides with Infleqtion’s pending public listing through a merger with Churchill Capital Corp X (NASDAQ: CCCX), which is expected to close on February 13, 2026. Following the close, the company will list on the New York Stock Exchange (NYSE) under the symbol “INFQ” on February 17, providing an estimated $540 million in gross proceeds to scale its neutral-atom hardware and software platforms. This clinical initiative follows Infleqtion’s recent technical milestones, including achieving 99.93% qubit measurement fidelity and demonstrating 12 logical qubits with error detection, positioning the company to execute complex healthcare algorithms on its near-term hardware roadmap.
Read the official announcement from Infleqtion here and the technical research paper on arXiv here.
February 6, 2026
